安徽医科大学学报2012，Vol.47Issue(7)：809-812,4.
重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合芍药苷对人滑膜细胞增殖的影响及部分机制
The influence of Paeoniflorin and recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein on human synovial cells and part mechanism
摘要
Abstract
Objective To investigate the regulatory effects of rhTNFR: Fc and Paeoniflorin( Pae ) combination therapy on fibroblast-like synoviocyte ( FLS ) proliferation, and to explore the regulatory role of Pae on the TNFR signaling pathway. Methods Informed consent, we collected normal synovial tissue of patients with hip arthroplas-ty, and cultured human synovial cells with tissue block method. Took the three generations of FLS, and then gave Pae( 10 -5 mol/L )and rhTNFR :Fc( 10 mg/L )and combination therapy. The proliferative response of human FLS was detected by MTT method, and TNFR1, TRAF2, TRADD expression in FLS were detected by semi-quantitative analysis of the immunohistochemical method. Results The proliferation experiments showed that the Pae and rhTNFR : Fc combination therapy group on the efficacy of F1S proliferation, which were better than that of the Pae alone group. Immunohistochemical experiments showed that Pae and rhTNFR: Fc both could downregulate the TNFR1 and TRAF2 expression, and upregulate TRADD expression in FLS. Conclusion Pae and rhTNFR: Fc combination therapy is superior to monotherapy with FLS, and the mechanism may be achieved by regulating the TRADD.关键词
芍药苷/重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/滑膜细胞/增殖/肿瘤坏死因子受体Key words
Paeoniflorin/ rhTNFR: Fc/ synovial cells/ proliferation/ TNFR分类
医药卫生引用本文复制引用
解国雄,吴华勋,陈镜宇,魏伟..重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合芍药苷对人滑膜细胞增殖的影响及部分机制[J].安徽医科大学学报,2012,47(7):809-812,4.基金项目
国家自然科学基金(编号:30973543 （）
81173075) （）
安徽省高校自然科学基金 (编号:KJ2011Z181 （）
KJ2011Z180) （）
